AstraZeneca Sweden Sweden
Research
Date range: 1 February 2022 - 31 January 2023
Parent institution:AstraZeneca plc
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for AstraZeneca Sweden published between 1 February 2022 - 31 January 2023 which are tracked by the Nature Index.
Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
| Count | Share |
|---|---|
| 29 | 8.27 |
Outputs by subject (Share)
| Subject | Count | Share |
|---|---|---|
| Life Sciences | 17 | 4.45 |
| Physical Sciences | 3 | 0.56 |
| Chemistry | 10 | 3.27 |
Share output for the past 5 years
| 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| 5.58 | 10.67 | 9.47 | 9.99 | 9.55 |
Nature Strategy Reports
Nature Strategy Reports gives you simple insights to support decisions that impact your organisation
The reports created for you by our subject matter experts combine compelling insights with Nature’s trust and authority. Get an in-depth analysis of your and your peers’ research performance, including a breakdown of relative strengths and weaknesses. All of which is crafted using data and tools from across Nature Research Intelligence, covering all major disciplines and all regions of the world.
Relationships
AstraZeneca Sweden
Affiliated joint institutions and consortia
- AstraZeneca-Max Planck Launch Cardiovascular and Metabolic Disease (CVMD) Collaboration
- Berzelii Center EXSELENT on Porous Materials
- International Consortium for Blood Pressure (ICBP)
- KI-AZ Integrated Cardio Metabolic Centre (ICMC)
- The Esophageal Adenocarcinoma GenEtics Consortium (EAGLE)
- The QT Interval International GWAS Consortium (QT-IGC)
Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.